The Intestinal Immunomodulation research group of the Department of Pharmacology of the University of Granada is integrated in the group Pharmacology of Natural Products (CTS-164) of the Andalusian Research Plan, as well as in the Institute of Biosanitary Research of Granada (ibs.GRANADA) (MP16). We are a research team of excellence dedicated to understanding how the interaction between the immune system, the microbiota and gut function influences health and the development of inflammatory, metabolic and digestive diseases.

Our goal is to transform this knowledge into innovative therapeutic solutions that improve people's quality of life. With a translational and interdisciplinary approach, we integrate basic, clinical and nutritional research to translate laboratory findings into medical practice.

We have extensive experience in advanced immunological analysis, in vitro and in vivo models of inflammation, metabolic syndrome and colorectal cancer, and in which we assess the modulation of the intestinal microbiota by means of different therapeutic strategies, including probiotics, prebiotics, natural extracts, bacterial metabolites, as well as natural or synthesised compounds.

In addition, we are leaders in the characterisation of functional foods and bioactive compounds, and the anti-inflammatory and immunomodulatory effect of nutraceuticals and drugs.  

The MP16 group offers unique capabilities in:

• Research and analysis: assessment of immunomodulatory activity, analysis of cytokines, biomarkers and microbiota using omics techniques.
• Technology development: design and validation of probiotic and symbiotic formulations, customised cell models and efficacy and safety testing.
• Collaboration and innovation: joint R&D projects, technology transfer and scientific advice for the development of functional products and immunomodulatory therapies.

Our goal is to advance cutting-edge therapeutic strategies, fostering innovation in the field of digestive health, microbiota and precision personalised medicine.